Home » Articles » Building early foundations for long-term OSD success

Building early foundations for long-term OSD success

Tablets and capsules remain the most familiar way patients take their medicines, yet the molecules entering today’s small-molecule pipelines are rarely as straightforward as the dosage forms that will eventually deliver them. Poorly soluble and highly potent APIs present significant development challenges, while modified-release requirements and specialized manufacturing processes can add complexity to otherwise conventional dosage forms. Programs are also expected to move quickly from one milestone to the next. Decisions made during the earliest stages of development carry significant weight, as API, excipient, formulation, and process choices can determine how readily a product ultimately scales to clinical and commercial production.

 

The organizations making those decisions are changing as well. According to the IQVIA Institute, 65% of novel active substances launched globally between 2020 and 2024 originated from emerging biopharma companies. Many of these developers do not have dedicated formulation, analytical, scale-up, or commercial manufacturing capabilities in-house. Partnering with an experienced CDMO gives them access to that expertise without substantial investment in facilities and personnel while helping them anticipate downstream challenges before they turn into costly rework.

 

Characterization as a first line of risk mitigation

 

A robust formulation and a scalable process both depend on a thorough understanding of the material being formulated. Pre-formulation work examines how soluble and permeable an API is, which solid-state form offers the right balance of solubility, stability, and processability, and how particle properties will behave in manufacturing equipment. Particle size distribution influences flow, content uniformity, dissolution, and compaction, while the choice between crystalline and amorphous forms often means trading physical stability against bioavailability.

 

Characterization is thus less a preliminary task than an early investment in risk reduction. It can reveal properties that might compromise later stages, such as a crystal form prone to conversion during processing or an API with demanding cleaning requirements. These findings also steer development toward strategies that are actually feasible in the long term. An experienced CDMO can interpret that data in context, recognizing from previous programs which findings are likely to matter at scale.

 

Formulating with the full lifecycle in mind

 

A successful OSD formulation also needs to balance drug performance with the practical realities of commercialization. It must deliver the intended exposure, meaning a poorly soluble API may require enabling approaches like particle-size reduction or amorphous solid dispersions produced through hot-melt extrusion or spray drying. It must also remain stable over its full shelf life, so stability studies should begin early and reflect the final dosage form and packaging configuration rather than the molecule alone.

 

Patients and markets belong in the conversation from the start. Tablet size, dosing frequency, and palatability can all affect adherence, particularly among pediatric and older populations. Excipients, colorants, and packaging formats need to satisfy the requirements of every region where the product will be sold. A material selected purely for its functionality may also be difficult to source reliably in commercial quantities, and changing an excipient, grade, or supplier late in development can introduce comparability, stability, and regulatory risks that earlier planning would have avoided.

 

Designing for scale and assessing results

 

Scale-up is rarely just a matter of making a process bigger, making it a common source of risk for drug developers. Larger equipment can change mixing times, shear forces, and heat transfer, while greater material volumes may amplify flow and segregation problems. Handling larger quantities of API, excipients, and solvents also introduces additional ergonomic and environmental, health, and safety (EHS) considerations. Because key process parameters often do not scale linearly, a method that works well at the bench may behave quite differently in a commercial suite. A Quality by Design framework helps teams prepare for this by starting with the end in mind: defining the quality target product profile, identifying the critical quality attributes (CQAs) that support it, and then determining which material attributes and process parameters must be controlled to achieve them.

 

Analytical development is what gives teams confidence that those controls are working. Methods should be tied to specific CQAs and be discriminating enough to detect changes that genuinely affect quality or performance. Validation rigor increases as a program advances, and methods must perform consistently wherever they are run so that data generated at different sites and scales remain comparable. As teams gather more data over time, processes can be refined further.

 

All of this knowledge has to survive the transition between teams and facilities. Gaps in technology and knowledge transfer can leave critical process understanding behind at the sending site, which is why continuity from development through commercial manufacturing matters so much. Bora’s strategic alliance with Corealis Pharma, formed in December 2025, was designed with this continuity in mind. The partnership unites Corealis’ expertise in formulation development and clinical-scale manufacturing with Bora’s global commercial infrastructure to support OSD programs end to end.

 

Building a foundation that lasts

 

No development program can eliminate every source of uncertainty. What a strategic approach to the earliest stages can do is help sponsors identify, understand, and manage risk before it leads to delays or late-stage redevelopment. For emerging biopharma companies in particular, an experienced CDMO partner can connect these decisions across the product lifecycle and turn early development work into a lasting foundation for commercial success.

You're leaving our site

You are being redirected to BoraBiologics.com